Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis

NCT06843239 is registered in ClinicalTrials.gov with Zura Bio Inc as lead sponsor.

NCT NCT06843239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06843239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis
Lead sponsor
Zura Bio Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 6, 2025
Completion date
January 31, 2028
Enrollment
80 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, systemic sclerosis (ssc)